SCHEMBL2880814

SCHEMBL2880814

COc1ccc(-c2nnc(Cl)c3cccnc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 2/20 0.50
CLK4 Q9HAZ1 1/20 0.46
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
MAOB P27338 2/20 0.42
GLO1 Q04760 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
SYK P43405 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CKS1B P61024 2/20 0.40
SKP2 Q13309 2/20 0.40
HSP90AA1 P07900 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884022 0.89 ALDH1A1 (0.50) ALDH1A1HPGDKDM4ECLK4NPSR1
SCHEMBL7617663 0.82 ALDH1A1 (0.41) ALDH1A1KDM4ENPSR1LMNAHTT
SCHEMBL1396133 0.80 NPSR1 (0.57) ALDH1A1KDM4ENPSR1LMNAHTT
SCHEMBL31359827 0.80 NPSR1 (0.57) ALDH1A1KDM4ENPSR1LMNAHTT
SCHEMBL4122604 0.73 PDE4A (0.47) ALDH1A1KDM4ENPSR1LMNAHTT
SCHEMBL9375383 0.72 KDM4E (0.51) ALDH1A1HPGDKDM4ECLK4NPSR1
SCHEMBL2887717 0.72 NPSR1 (0.43) ALDH1A1HPGDKDM4ENPSR1LMNA
SCHEMBL31359869 0.72 NPSR1 (0.43) ALDH1A1HPGDKDM4ENPSR1LMNA
SCHEMBL2887372 0.72 KDM4E (0.54) ALDH1A1HPGDKDM4ECLK4NPSR1
SCHEMBL30108849 0.72 G6PD (0.44) ALDH1A1HPGDKDM4ENPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 ALDH1A1 1934/4885HPGD 573/4885KDM4E 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.